DalsnaFinance Account

Solventum $SOLV

Health Care · Health Care Technology · NYSE/NASDAQ

S&P 500 Russell 1000 Minnesota

Create a scorecard

$87.26

+0.96 (+1.11%)

As of Oct 15, 2026, 1:38 AM EDT

Price history

Loading chart…

Solventum (SOLV) is trading up at $87.26 (+1.11%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.

Solventum revenue & net income history (FY2022–FY2025)

RevenueNet incomeNet margin (right axis, %)

Solventum annual financial statements
	FY2022Dec 2022	FY2023Dec 2023	FY2024Dec 2024	FY2025Dec 2025
Income statement
Revenue	$8.13B	$8.20B	$8.25B	$8.32B
Growth (year over year)	—	+0.8%	+0.7%	+0.9%
Gross profit	$4.70B	$4.69B	$4.59B	$4.45B
Gross margin	57.7%	57.3%	55.6%	53.5%
Operating income	$1.69B	$1.69B	$1.04B	$2.18B
Operating margin	20.8%	20.6%	12.6%	26.2%
Net income	$1.34B	$1.35B	$479.0M	$1.56B
Net margin	16.5%	16.4%	5.8%	18.7%
EPS (diluted)	$7.78	$7.79	$2.76	$8.88
Balance sheet
Cash and equivalents	$61.0M	$194.0M	$762.0M	$878.0M
Total assets	—	$13.9B	$14.5B	$14.3B
Total liabilities	—	$2.28B	$11.5B	$9.24B
Long-term debt	—	$0	$7.81B	$5.04B
Shareholders' equity	$11.7B	$11.7B	$2.96B	$5.05B
Cash flow
Operating cash flow	$1.68B	$1.92B	$1.19B	$369.0M
Capital expenditure	$251.0M	$290.0M	$380.0M	$379.0M
Free cash flow	$1.43B	$1.63B	$805.0M	−$10.0M

RevenueNet incomeNet margin (right axis, %)

Solventum quarterly financial statements
	Q3 FY24Sep 2024	Q4 FY24^†Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25^†Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Income statement
Revenue	$2.08B	$2.08B	$2.07B	$2.16B	$2.10B	$2.00B	$2.01B	$2.21B
Growth (year over year)	+0.4%	+1.9%	+2.7%	+3.8%	+0.7%	−3.7%	−3.0%	+2.2%
Gross profit	$1.17B	$1.12B	$1.11B	$1.18B	$1.14B	$1.03B	$1.10B	$1.29B
Gross margin	56.0%	53.9%	53.8%	54.4%	54.2%	51.4%	54.7%	58.2%
Operating income	$275.0M	$136.0M	$152.0M	$214.0M	$1.69B	$125.0M	$81.0M	$181.0M
Operating margin	13.2%	6.6%	7.3%	9.9%	80.6%	6.3%	4.0%	8.2%
Net income	$122.0M	$31.0M	$137.0M	$90.0M	$1.27B	$63.0M	$13.0M	$92.0M
Net margin	5.9%	1.5%	6.6%	4.2%	60.4%	3.2%	0.6%	4.2%
EPS (diluted)	$0.70	$0.18	$0.78	$0.51	$7.22	$0.37	$0.07	$0.53
Balance sheet
Cash and equivalents	$772.0M	$762.0M	$534.0M	$492.0M	$1.64B	$878.0M	$561.0M	$403.0M
Total assets	$14.7B	$14.5B	$14.5B	$15.1B	$14.0B	$14.3B	$14.1B	$14.2B
Total liabilities	$11.6B	$11.5B	$11.3B	$11.4B	$8.99B	$9.24B	$9.13B	$9.44B
Long-term debt	$7.81B	$7.81B	$7.81B	$7.82B	$5.14B	$5.04B	$4.58B	$4.57B
Shareholders' equity	$3.19B	$2.96B	$3.26B	$3.65B	$4.99B	$5.05B	$4.97B	$4.80B
Cash flow
Operating cash flow	$169.0M	$219.0M	$29.0M	$169.0M	$76.0M	$95.0M	−$189.0M	$227.0M
Capital expenditure	$93.0M	$127.0M	$109.0M	$110.0M	$97.0M	$63.0M	$84.0M	$83.0M
Free cash flow	$76.0M	$92.0M	−$80.0M	$59.0M	−$21.0M	$32.0M	−$273.0M	$144.0M
Share buybacks	—	—	$0	$0	—	—	$67.0M	$288.0M

From Solventum's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →